Cargando…
GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor
In recent years mesenchymal stromal cells (MSCs) have received a great deal of interest for the treatment of major diseases, but clinical translation and market authorization have been slow. This has been due in part to a lack of standardization in cell manufacturing protocols, as well as a lack of...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959900/ https://www.ncbi.nlm.nih.gov/pubmed/35356775 http://dx.doi.org/10.3389/fbioe.2022.834267 |
_version_ | 1784677265226858496 |
---|---|
author | Fitzgerald, Joan C. Duffy, Niamh Cattaruzzi, Giacomo Vitrani, Francesco Paulitti, Alice Mazzarol, Flavia Mauro, Prisca Sfiligoj, Antonio Curcio, Francesco Jones, Deirdre M. McInerney, Veronica Krawczyk, Janusz Kelly, Jack Finnerty, Andrew McDonagh, Katya McCabe, Una Duggan, Matthew Connolly, Lauren Shaw, Georgina Murphy, Mary Barry, Frank |
author_facet | Fitzgerald, Joan C. Duffy, Niamh Cattaruzzi, Giacomo Vitrani, Francesco Paulitti, Alice Mazzarol, Flavia Mauro, Prisca Sfiligoj, Antonio Curcio, Francesco Jones, Deirdre M. McInerney, Veronica Krawczyk, Janusz Kelly, Jack Finnerty, Andrew McDonagh, Katya McCabe, Una Duggan, Matthew Connolly, Lauren Shaw, Georgina Murphy, Mary Barry, Frank |
author_sort | Fitzgerald, Joan C. |
collection | PubMed |
description | In recent years mesenchymal stromal cells (MSCs) have received a great deal of interest for the treatment of major diseases, but clinical translation and market authorization have been slow. This has been due in part to a lack of standardization in cell manufacturing protocols, as well as a lack of biologically meaningful cell characterization tools and release assays. Cell production strategies to date have involved complex manual processing in an open environment which is costly, inefficient and poses risks of contamination. The NANT 001 bioreactor has been developed for the automated production of small to medium cell batches for autologous use. This is a closed, benchtop system which automatically performs several processes including cell seeding, media change, real-time monitoring of temperature, pH, cell confluence and cell detachment. Here we describe a validation of the bioreactor in an environment compliant with current good manufacturing practice (cGMP) to confirm its utility in replacing standardized manual processing. Stromal vascular fraction (SVF) was isolated from lipoaspirate material obtained from healthy donors. SVF cells were seeded in the bioreactor. Cell processing was performed automatically and cell harvesting was triggered by computerized analysis of images captured by a travelling microscope positioned beneath the cell culture flask. For comparison, the same protocol was performed in parallel using manual methods. Critical quality attributes (CQA) assessed for cells from each process included cell yield, viability, surface immunophenotype, differentiation propensity, microbial sterility and endotoxin contamination. Cell yields from the bioreactor cultures were comparable in the manual and automated cultures and viability was >90% for both. Expression of surface markers were consistent with standards for adipose-derived stromal cell (ASC) phenotype. ASCs expanded in both automated and manual processes were capable of adipogenic and osteogenic differentiation. Supernatants from all cultures tested negative for microbial and endotoxin contamination. Analysis of labor commitment indicated considerable economic advantage in the automated system in terms of operator, quality control, product release and management personnel. These data demonstrate that the NANT 001 bioreactor represents an effective option for small to medium scale, automated, closed expansion of ASCs from SVF and produces cell products with CQA equivalent to manual processes. |
format | Online Article Text |
id | pubmed-8959900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89599002022-03-29 GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor Fitzgerald, Joan C. Duffy, Niamh Cattaruzzi, Giacomo Vitrani, Francesco Paulitti, Alice Mazzarol, Flavia Mauro, Prisca Sfiligoj, Antonio Curcio, Francesco Jones, Deirdre M. McInerney, Veronica Krawczyk, Janusz Kelly, Jack Finnerty, Andrew McDonagh, Katya McCabe, Una Duggan, Matthew Connolly, Lauren Shaw, Georgina Murphy, Mary Barry, Frank Front Bioeng Biotechnol Bioengineering and Biotechnology In recent years mesenchymal stromal cells (MSCs) have received a great deal of interest for the treatment of major diseases, but clinical translation and market authorization have been slow. This has been due in part to a lack of standardization in cell manufacturing protocols, as well as a lack of biologically meaningful cell characterization tools and release assays. Cell production strategies to date have involved complex manual processing in an open environment which is costly, inefficient and poses risks of contamination. The NANT 001 bioreactor has been developed for the automated production of small to medium cell batches for autologous use. This is a closed, benchtop system which automatically performs several processes including cell seeding, media change, real-time monitoring of temperature, pH, cell confluence and cell detachment. Here we describe a validation of the bioreactor in an environment compliant with current good manufacturing practice (cGMP) to confirm its utility in replacing standardized manual processing. Stromal vascular fraction (SVF) was isolated from lipoaspirate material obtained from healthy donors. SVF cells were seeded in the bioreactor. Cell processing was performed automatically and cell harvesting was triggered by computerized analysis of images captured by a travelling microscope positioned beneath the cell culture flask. For comparison, the same protocol was performed in parallel using manual methods. Critical quality attributes (CQA) assessed for cells from each process included cell yield, viability, surface immunophenotype, differentiation propensity, microbial sterility and endotoxin contamination. Cell yields from the bioreactor cultures were comparable in the manual and automated cultures and viability was >90% for both. Expression of surface markers were consistent with standards for adipose-derived stromal cell (ASC) phenotype. ASCs expanded in both automated and manual processes were capable of adipogenic and osteogenic differentiation. Supernatants from all cultures tested negative for microbial and endotoxin contamination. Analysis of labor commitment indicated considerable economic advantage in the automated system in terms of operator, quality control, product release and management personnel. These data demonstrate that the NANT 001 bioreactor represents an effective option for small to medium scale, automated, closed expansion of ASCs from SVF and produces cell products with CQA equivalent to manual processes. Frontiers Media S.A. 2022-03-09 /pmc/articles/PMC8959900/ /pubmed/35356775 http://dx.doi.org/10.3389/fbioe.2022.834267 Text en Copyright © 2022 Fitzgerald, Duffy, Cattaruzzi, Vitrani, Paulitti, Mazzarol, Mauro, Sfiligoj, Curcio, Jones, McInerney, Krawczyk, Kelly, Finnerty, McDonagh, McCabe, Duggan, Connolly, Shaw, Murphy and Barry. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Fitzgerald, Joan C. Duffy, Niamh Cattaruzzi, Giacomo Vitrani, Francesco Paulitti, Alice Mazzarol, Flavia Mauro, Prisca Sfiligoj, Antonio Curcio, Francesco Jones, Deirdre M. McInerney, Veronica Krawczyk, Janusz Kelly, Jack Finnerty, Andrew McDonagh, Katya McCabe, Una Duggan, Matthew Connolly, Lauren Shaw, Georgina Murphy, Mary Barry, Frank GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor |
title | GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor |
title_full | GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor |
title_fullStr | GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor |
title_full_unstemmed | GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor |
title_short | GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor |
title_sort | gmp-compliant production of autologous adipose-derived stromal cells in the nant 001 closed automated bioreactor |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959900/ https://www.ncbi.nlm.nih.gov/pubmed/35356775 http://dx.doi.org/10.3389/fbioe.2022.834267 |
work_keys_str_mv | AT fitzgeraldjoanc gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT duffyniamh gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT cattaruzzigiacomo gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT vitranifrancesco gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT paulittialice gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT mazzarolflavia gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT mauroprisca gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT sfiligojantonio gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT curciofrancesco gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT jonesdeirdrem gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT mcinerneyveronica gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT krawczykjanusz gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT kellyjack gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT finnertyandrew gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT mcdonaghkatya gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT mccabeuna gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT dugganmatthew gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT connollylauren gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT shawgeorgina gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT murphymary gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor AT barryfrank gmpcompliantproductionofautologousadiposederivedstromalcellsinthenant001closedautomatedbioreactor |